勃林格殷格翰管理层于周五向专家组提出解释意见时又掀起了这场争论。
Boehringer Ingelheim officials invoked that debate as they made their case to experts Friday.
2010年，勃林格殷格翰公司的净销售额达126亿欧元。公司将其最大业务-处方药业务销售额的24%投入于研发。
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.
应用推荐